At close: December 20 at 4:00:00 PM EST
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
Operating Cash Flow
-2,945.3670
-2,945.3670
-1,592.0800
-1,396.4220
Investing Cash Flow
-5.7270
-5.7270
--
-32.0395
Financing Cash Flow
2,350.0000
2,350.0000
1,172.9230
-1,627.5764
End Cash Position
733.1880
733.1880
1,334.2800
1,755.0382
Capital Expenditure
-5.7270
-5.7270
--
--
Issuance of Debt
2,500.0000
2,500.0000
--
--
Repayment of Debt
-150.0000
-150.0000
--
--
Free Cash Flow
-2,951.0940
-2,951.0940
-1,592.0800
-1,396.4220
-
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CEROW CERo Therapeutics Holdings, Inc.
0.0090
-14.29%
ABPWW Abpro Holdings, Inc.
0.1021
+106.26%
HUMAW Humacyte, Inc.
1.7400
+39.20%
TCBPW TC Biopharm (Holdings) Plc
0.0151
+37.27%
PTIXW Protagenic Therapeutics, Inc.
0.0080
0.00%
NKGN NKGen Biotech, Inc.
0.6400
+13.25%
DRMAW Dermata Therapeutics, Inc.
0.0147
+5.00%
JSPRW Jasper Therapeutics, Inc.
0.2300
+31.20%
APLMW Apollomics, Inc.
0.0125
+13.64%
REVBW Revelation Biosciences, Inc.
0.0086
+7.50%